Cargando…
The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs
A latent tuberculosis infection (LTBI) is a major source of active tuberculosis, and addressing an LTBI is crucial for the elimination of tuberculosis. The treatment of tuberculosis often requires a 6-month course of multidrug therapy, and for drug-resistant tuberculosis, a longer course of multidru...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781032/ https://www.ncbi.nlm.nih.gov/pubmed/36560574 http://dx.doi.org/10.3390/vaccines10122164 |
_version_ | 1784856974234484736 |
---|---|
author | Guo, Xiaonan Lu, Jinbiao Li, Junli Du, Weixin Shen, Xiaobing Su, Cheng Wu, Yongge Zhao, Aihua Xu, Miao |
author_facet | Guo, Xiaonan Lu, Jinbiao Li, Junli Du, Weixin Shen, Xiaobing Su, Cheng Wu, Yongge Zhao, Aihua Xu, Miao |
author_sort | Guo, Xiaonan |
collection | PubMed |
description | A latent tuberculosis infection (LTBI) is a major source of active tuberculosis, and addressing an LTBI is crucial for the elimination of tuberculosis. The treatment of tuberculosis often requires a 6-month course of multidrug therapy, and for drug-resistant tuberculosis, a longer course of multidrug therapy is needed, which has many drawbacks. At present, vaccines are proposed as an adjunct to chemotherapy to protect populations with an LTBI and delay its recurrence. In this study, we analyzed the protective effect of a novel subunit vaccine, AEC/BC02, in a guinea pig latent infection model. Through the optimization of different chemotherapy durations and immunization times, it was found that 4 weeks of administration of isoniazid–rifampin tablets combined with three or six injections of the vaccine could significantly reduce the gross pathological score and bacterial load in organs and improve the pathological lesions. This treatment regimen had a better protective effect than the other administration methods. Furthermore, no drug resistance of Mycobacterium tuberculosis was detected after 2 or 4 weeks of administration of the isoniazid–rifampin tablets, indicating a low risk of developing drug-resistant bacteria during short-term chemotherapy. The above results provided the foundation for an AEC/BC02 clinical protocol. |
format | Online Article Text |
id | pubmed-9781032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97810322022-12-24 The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs Guo, Xiaonan Lu, Jinbiao Li, Junli Du, Weixin Shen, Xiaobing Su, Cheng Wu, Yongge Zhao, Aihua Xu, Miao Vaccines (Basel) Article A latent tuberculosis infection (LTBI) is a major source of active tuberculosis, and addressing an LTBI is crucial for the elimination of tuberculosis. The treatment of tuberculosis often requires a 6-month course of multidrug therapy, and for drug-resistant tuberculosis, a longer course of multidrug therapy is needed, which has many drawbacks. At present, vaccines are proposed as an adjunct to chemotherapy to protect populations with an LTBI and delay its recurrence. In this study, we analyzed the protective effect of a novel subunit vaccine, AEC/BC02, in a guinea pig latent infection model. Through the optimization of different chemotherapy durations and immunization times, it was found that 4 weeks of administration of isoniazid–rifampin tablets combined with three or six injections of the vaccine could significantly reduce the gross pathological score and bacterial load in organs and improve the pathological lesions. This treatment regimen had a better protective effect than the other administration methods. Furthermore, no drug resistance of Mycobacterium tuberculosis was detected after 2 or 4 weeks of administration of the isoniazid–rifampin tablets, indicating a low risk of developing drug-resistant bacteria during short-term chemotherapy. The above results provided the foundation for an AEC/BC02 clinical protocol. MDPI 2022-12-16 /pmc/articles/PMC9781032/ /pubmed/36560574 http://dx.doi.org/10.3390/vaccines10122164 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Guo, Xiaonan Lu, Jinbiao Li, Junli Du, Weixin Shen, Xiaobing Su, Cheng Wu, Yongge Zhao, Aihua Xu, Miao The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs |
title | The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs |
title_full | The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs |
title_fullStr | The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs |
title_full_unstemmed | The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs |
title_short | The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs |
title_sort | subunit aec/bc02 vaccine combined with antibiotics provides protection in mycobacterium tuberculosis-infected guinea pigs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781032/ https://www.ncbi.nlm.nih.gov/pubmed/36560574 http://dx.doi.org/10.3390/vaccines10122164 |
work_keys_str_mv | AT guoxiaonan thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT lujinbiao thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT lijunli thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT duweixin thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT shenxiaobing thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT sucheng thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT wuyongge thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT zhaoaihua thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT xumiao thesubunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT guoxiaonan subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT lujinbiao subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT lijunli subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT duweixin subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT shenxiaobing subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT sucheng subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT wuyongge subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT zhaoaihua subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs AT xumiao subunitaecbc02vaccinecombinedwithantibioticsprovidesprotectioninmycobacteriumtuberculosisinfectedguineapigs |